Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
US11091495B2 · kind B2 · utility
4Cited by
24References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 9, 2020 |
| Grant date | Aug 17, 2021 |
| Priority date | — |
| Expiry date | Dec 9, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions of the present invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.